Epidemiology, treatment, and guidelines for the treatment of heart failure in Europe

European Heart Journal, Supplement

Volumn 7, Issue J, 2005, Pages

  Tendera, Michal ^a  

^a MEDICAL UNIVERSITY OF SILESIA   (Poland)

Author keywords

Chronic heart failure; Epidemiology; Europe; Treatment

Indexed keywords

ALDOSTERONE ANTAGONIST; ANGIOTENSIN RECEPTOR ANTAGONIST; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CANDESARTAN; CARVEDILOL; DIGOXIN; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; DIURETIC AGENT; ENALAPRIL; EPLERENONE; LOOP DIURETIC AGENT; LOSARTAN; SPIRONOLACTONE; THIAZIDE DIURETIC AGENT; VALSARTAN;

ACUTE HEART FAILURE; AGING; CARDIOVASCULAR RISK; CLINICAL TRIAL; DIAGNOSTIC ACCURACY; EUROPE; EVIDENCE BASED MEDICINE; HEALTH CARE; HEALTH CARE COST; HEALTH PRACTITIONER; HEART FAILURE; HUMAN; PRACTICE GUIDELINE; PRIORITY JOURNAL; PROGNOSIS; QUALITY OF LIFE; REVIEW; SURVIVAL TIME;

EID: 26644431834     PISSN: 1520765X     EISSN: None     Source Type: Journal    
DOI: 10.1093/eurheartj/sui056     Document Type: Review

References (52)

1. Remme WJ, Swedberg K, The Task Force for the Diagnosis and Treatment of Chronic Heart Failure of the European Society of Cardiology. Guidelines for the diagnosis and treatment of chronic heart failure. Eur Heart J 2001;22:1527-1560.
2. Gibbs LM, Addington-Hall J, Gibbs JS. Dying from heart failure: lessons from palliative care. Many patients would benefit from palliative care at the end of their lives. BMJ 1998;317:961-962.
3. McMurray J, McDonagh T, Morrison CE et al. Trends in hospitalization for heart failure in Scotland 1980-1990. Eur Heart J 1993;14:1158-1162.
4. Stewart S, MacIntyre K, Hole DJ et al. More 'malignant' than cancer? Five-year survival following a first admission for heart failure. Eur J Heart Fail 2001;3:315-322.
5. Dargie HJ, McMurray JJ. Diagnosis and management of heart failure. BMJ 1994;308:321-328.
6. De Luca L, Gheorghiade M. Hospitalization for worsening heart failure. Ital Heart J 2004;5(Suppl.):S55-S62.
7. Croft JB, Giles WH, Pollard RA et al. Heart failure survival among older adults in the United States: a poor prognosis for an emerging epidemic in the Medicare population. Arch Intern Med 1999;159:505-510.
8. Bertoni AG, Hundley WG, Massing MW et al. Heart failure prevalence, incidence, and mortality in the elderly with diabetes. Diabetes Care 2004;27:699-703.
9. Bell DS. Heart failure: the frequent, forgotten, and often fatal complication of diabetes. Diabetes Care 2003;26:2433-2441.
10. Albert NM, Davis M, Young J. Improving the care of patients dying of heart failure. Cleve Clin J Med 2002;69:321-328.
11. McMurray JJV, Stewart S. The burden of heart failure. Eur Heart J 2003;5(Suppl.):I3-I13.
12. Davis RC, Hobbs FD, Kenkre JE et al. Prevalence of left ventricular systolic dysfunction and heart failure in high risk patients: community based epidemiological study. BMJ 2002;325:1156.
13. Davidson PM, Paull G, Introna K et al. Integrated, collaborative palliative care in heart failure: the St. George Heart Failure Service experience 1999-2002. J Cardiovasc Nurs 2004;19:68-75.
14. Cleland JG, Swedberg K, Follath F et al. The EuroHeart Failure survey programme - a survey on the quality of care among patients with heart failure in Europe. Part 1: patient characteristics and diagnosis. Eur Heart J 2003;24:442-463.
15. Cowie MR, Wood DA, Coats AJ et al. Incidence and aetiology of heart failure: a population-based study. Eur Heart J 1999;20:421-428.
16. Mosterd A, Hoes AW, de Bruyne MC et al. Prevalence of heart failure and left ventricular dysfunction in the general population: the Rotterdam Study. Eur Heart J 1999;20:447-455.
17. Vasan RS, Levy D. Defining diastolic heart failure: a call for standardized diagnostic criteria. Circulation 2000;101:2118-2121.
18. Goff DC Jr, Pandey DK, Chan FA et al. Congestive heart failure in the United States: is there more than meets the I(CD code)? The Corpus Christi Heart Project. Arch Intern Med 2000;160:197-202.
19. Hogg K, Swedberg K, McMurray J. Heart failure with preserved left ventricular systolic function; epidemiology, clinical characteristics, and prognosis. J Am Coll Cardiol 2004;43:317-327.
20. McKee SP, Leslie SJ, LeMaitre JP et al. Management of chronic heart failure due to systolic left ventricular dysfunction by cardiologist and non-cardiologist physicians. Eur J Heart Fail 2003;5:549-555.
21. The CONSENSUS Trial Study Group. Effects of enalapril on mortality in severe congestive heart failure. Results of the Cooperative North Scandinavian Enalapril Survival Study (CONSENSUS). The CONSENSUS Trial Study Group. N Engl J Med 1987;316:1429-1435.
22. The SOLVD Investigators. Effect of enalapril on survival in patients with reduced left ventricular ejection fractions and congestive heart failure. N Engl J Med 1991;325:293-302.
23. Garg R, Yusuf S. Overview of randomized trials of angiotensin-converting enzyme inhibitors on mortality and morbidity in patients with heart failure. Collaborative Group on ACE Inhibitor Trials. JAMA 1995;273:1450-1456.
24. Jong P, Yusuf S, Rousseau MF et al. Effect of enalapril on 12-year survival and life expectancy in patients with left ventricular systolic dysfunction: a follow-up study. Lancet 2003;361:1843-1848.
25. Shekelle PG, Rich MW, Morton SC et al. Efficacy of angiotensin-converting enzyme inhibitors and beta-blockers in the management of left ventricular systolic dysfunction according to race, gender, and diabetic status: a meta-analysis of major clinical trials. J Am Coll Cardiol 2003;41:1529-1538.
26. Lopez-Sendon J, Swedberg K, McMurray J et al. Expert consensus document on angiotensin converting enzyme inhibitors in cardiovascular disease. The Task Force on ACE-inhibitors of the European Society of Cardiology. Eur Heart J 2004;25:1454-1470.
27. Swedberg K, Kjekshus J, Snapinn S. Long-term survival in severe heart failure in patients treated with enalapril. Ten year follow-up of CONSENSUS I. Eur Heart J 1999;20:136-139.
28. Faris R, Flather M, Purcell H et al. Current evidence supporting the role of diuretics in heart failure: a meta analysis of randomised controlled trials. Int J Cardiol 2002;82:149-158.
29. MERIT-HF Study Group. Effect of metoprolol CR/XL in chronic heart failure: Metoprolol CR/XL Randomised Intervention Trial in Congestive Heart Failure (MERIT-HF). Lancet 1999;353:2001-2007.
30. CIBIS II Investigators and Committees. The Cardiac Insufficiency Bisoprolol Study II (CIBIS-II): a randomised trial. Lancet 1999;353:9-13.
31. Hjalmarson A, Goldstein S, Fagerberg B et al. Effects of controlled-release metoprolol on total mortality, hospitalizations, and well-being in patients with heart failure: the Metoprolol CR/XL Randomized Intervention Trial in congestive heart failure (MERIT-HF). MERIT-HF Study Group. JAMA 2000;283:1295-1302.
32. Dargie HJ. Effect of carvedilol on outcome after myocardial infarction in patients with left-ventricular dysfunction: the CAPRICORN randomised trial. Lancet 2001;357:1385-1390.
33. Packer M, Fowler MB, Roecker EB et al. Effect of carvedilol on the morbidity of patients with severe chronic heart failure: results of the carvedilol prospective randomized cumulative survival (COPERNICUS) study. Circulation 2002;106:2194-2199.
34. Lopez-Sendon J, Swedberg K, McMurray J et al. Expert consensus document on beta-adrenergic receptor blockers. Eur Heart J 2004;25:1341-1362.
35. Komajda M, Lutiger B, Madeira H et al. Tolerability of carvedilol and ACE-Inhibition in mild heart failure. Results of CARMEN (Carvedilol ACE-Inhibitor Remodelling Mild CHF EvaluatioN). Eur J Heart Fail 2004;6:467-475.
36. Colucci WS, Packer M, Bristow MR et al. Carvedilol inhibits clinical progression in patients with mild symptoms of heart failure. US Carvedilol Heart Failure Study Group. Circulation 1996;94:2800-2806.
37. Packer M, Bristow MR, Cohn JN et al. The effect of carvedilol on morbidity and mortality in patients with chronic heart failure. U.S. Carvedilol Heart Failure Study Group. N Engl J Med 1996;334:1349-1355.
38. Packer M, Coats AJ, Fowler MB et al. Effect of carvedilol on survival in severe chronic heart failure. N Engl J Med 2001;344:1651-1658.
39. Pitt B, Zannad F, Remme WJ et al. The effect of spironolactone on morbidity and mortality in patients with severe heart failure. Randomized Aldactone Evaluation Study Investigators. N Engl J Med 1999;341:709-717.
40. Pitt B, Remme W, Zannad F et al. Eplerenone, a selective aldosterone blocker, in patients with left ventricular dysfunction after myocardial infarction. N Engl J Med 2003;348:1309-1321.
41. Pitt B, Reichek N, Willenbrock R et al. Effects of eplerenone, enalapril, and eplerenone/enalapril in patients with essential hypertension and left ventricular hypertrophy: the 4E-left ventricular hypertrophy study. Circulation 2003;108:1831-1838.
42. Cohn JN, Tognoni G. A randomized trial of the angiotensin-receptor blocker valsartan in chronic heart failure. N Engl J Med 2001;345:1667-1675.
43. Komajda M. Are angiotensin II receptor antagonists indicated in chronic heart failure? Heart Fail Monit 2002;2:85-87.
44. Pitt B, Poole-Wilson PA, Segal R et al. Effect of losartan compared with captopril on mortality in patients with symptomatic heart failure: randomised trial - the Losartan Heart Failure Survival Study ELITE II. Lancet 2000;355:1582-1587.
45. Maggioni AP, Anand I, Gottlieb SO et al. Effects of valsartan on morbidity and mortality in patients with heart failure not receiving angiotensin-converting enzyme inhibitors. J Am Coll Cardiol 2002;40:1414-1421.
46. Pfeffer MA, Swedberg K, Granger CB et al. Effects of candesartan on mortality and morbidity in patients with chronic heart failure: the CHARM-Overall programme. Lancet 2003;362:759-766.
47. McMurray JJ, Ostergren J, Swedberg K et al. Effects of candesartan in patients with chronic heart failure and reduced left-ventricular systolic function taking angiotensin-converting-enzyme inhibitors: The CHARM-Added trial. Lancet 2003;362:767-771.
48. Granger CB, McMurray JJ, Yusuf S et al. Effects of candesartan in patients with chronic heart failure and reduced left-ventricular systolic function intolerant to angiotensin-converting-enzyme inhibitors: the CHARM- Alternative trial. Lancet 2003;362:772-776.
49. Yusuf S, Pfeffer MA, Swedberg K et al. Effects of candesartan in patients with chronic heart failure and preserved left-ventricular ejection fraction: the CHARM-Preserved Trial. Lancet 2003;362:777-781.
50. Young JB, Dunlap ME, Pfeffer MA et al. Mortality and morbidity reduction with Candesartan in patients with chronic heart failure and left ventricular systolic dysfunction: results of the CHARM low-left ventricular ejection fraction trials. Circulation 2004;110:2618-2626.
51. Solomon SD, Wang D, Finn P et al. Effect of candesartan on cause-specific mortality in heart failure patients: the Candesartan in Heart failure Assessment of Reduction in Mortality and morbidity (CHARM) program. Circulation 2004;110:2180-2183.
52. Swedberg K, The Task Force for the Diagnosis and Treatment of Chronic Heart Failure of the European Society of Cardiology. Guidelines for the diagnosis and treatment of chronic heart failure. Eur Heart J 2005;26:1115-1140.